文献速递白血病MDS 与骨髓增殖性肿瘤

维奈克拉联合去甲基化药物治疗新诊断急性髓系白血病的应用策略

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
PubMed 文献 · Leukemia · 2019-10-18

本文针对维奈克拉联合去甲基化药物(HMA)方案治疗不适合强化疗的新诊断急性髓系白血病(AML)患者,总结了基于证据与经验的新兴管理策略。文章指出该方案虽高效但具有独特挑战,包括起效迅速、血细胞减少的程度与持续时间、药物相互作用等问题。

要点

  • 维奈克拉联合HMA适用于老年或不适合诱导化疗的新诊断AML患者
  • 需关注治疗中血细胞减少的速率与深度及药物相互作用
  • 本文基于证据与经验总结该联合方案的新兴管理策略

核心结论

  • 维奈克拉联合HMA是FDA批准用于老年或不适合诱导化疗的新诊断AML患者的一线治疗,具有独特的管理挑战。

研究设计与样本

  • 本文为基于证据与经验的综述性文章,总结维奈克拉联合HMA治疗新诊断AML的管理策略。

主要发现

  • 维奈克拉为口服BCL-2抑制剂,与HMA(阿扎胞苷或地西他滨)或低剂量阿糖胞苷联合用于AML一线治疗。
  • 该联合方案起效迅速,但伴随血细胞减少的速率与深度问题及药物相互作用等挑战。

关键数值与推荐

  • FDA批准维奈克拉联合HMA(阿扎胞苷或地西他滨)或低剂量阿糖胞苷用于老年或不适合诱导化疗的新诊断AML患者一线治疗。

临床怎么用

  • 临床使用维奈克拉联合HMA时需关注起效速度、血细胞减少的监测与处理及药物相互作用管理。

局限性

  • 本文为基于证据与经验的总结,非系统综述或前瞻性研究,未报告具体样本量或统计阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is associated with poor outcomes, especially in older patients in whom the disease is most common. B-cell lymphoma 2 (BCL-2) is an antiapoptotic protein involved in the survival and maintenance of AML, and it is overexpressed in the leukemia stem cell population. Venetoclax is an oral BCL-2 protein inhibitor recently approved by the United States Food and Drug Administration (FDA) for use in combination with a hypomethylating agent (HMA) (azacitidine or decitabine) or low-dose cytarabine for front-line treatment of AML in older patients or those unfit for induction chemotherapy. Given that its mechanism of action is unique, it is not surprising that this widely effective therapy presents unique challenges, including but not limited to the rapidity of responses, the rate and depth of cytopenias, and issues related to drug-drug interactions. With the recent FDA approval and increasingly widespread use, we aim here to summarize, based on evidence and experience, emerging management strategies for the combination of HMAs and venetoclax in the treatment of AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019. PMID: 31628431. doi:10.1038/s41375-019-0612-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。